Glycosyn LLC is a biotechnology company that focuses on developing products derived from natural molecules found in human milk. These products offer a wide range of health benefits by promoting the establishment and maintenance of a healthy gut microbial ecology. Working in collaboration with partners, Glycosyn explores the potential of these molecules in promoting normal healthy nutrition and combating various childhood and adult diseases, including inflammatory bowel disease, necrotizing enterocolitis, irritable bowel syndrome, infectious diarrhea, and childhood respiratory diseases.

Founded in 2002, Glycosyn aims to commercialize groundbreaking discoveries that emerged from three decades of academic research conducted by its scientific founders: David Newburg, Ardythe Morrow, and Guillermo Ruiz-Palacios. These researchers identified natural anti-infective components, known as glycans, in human breast milk that provide significant protection against infectious diarrhea. Under the leadership of Chief Scientific Officer Dr.

John McCoy, Glycosyn has developed scalable technology for the large-scale production of their principal products – human milk oligosaccharides (hMOS). This innovation has been supported by intellectual property to safeguard their advancements. Extensive research supported by the National Institutes of Health has shown that human milk contains thousands of bioactive glycan structures with unique functions to promote health.

Glycosyn has licensed intellectual property that covers several of these uses of human milk oligosaccharides. In summary, Glycosyn LLC utilizes the power of human milk science to enhance overall health by providing innovative products with significant health benefits